IDT Biologika specializes in the contract development and manufacturing of vaccines, gene therapy medicinal products, sterile liquids and lyophilized biologics. We help biopharmaceutical companies with the challenging and complex process of translating vaccines and other biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing, fill/finish, packaging and quality control. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilites meeting FDA and EMA standards (ANVISA ready).
We strive for strong and enduring partnerships with innovative biotech and world‘s leading biopharma companies. Our almost 100-year tradition of manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.
New building for vaccine production enables even more flexible reaction to customer demands more info
Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split more info
Divestment of animal health business unit enables focus on global growth market more info
Ceva Santé Animale and IDT Biologika GmbH announce agreement for Ceva to acquire the IDT animal health business, expanding its global vaccine portfolio and boosting swine innovation more info
RT @IMG_ST: Last Friday a multifunctional production facility for human virus production was inaugurated at the #Biopharmapark in #SaxonyAn… more info
RT @iitoLifeScience: IDT Biologika to Divest Animal Health Business Unit to Focus on Production of Human Vaccines & Medicines https://t.co/… more info
RT @CevaSanteAnimal: [Press Release] 📣 Ceva is proud to announce provisional agreement to acquire the animal health business of biopharmac… more info